Nafazatrom is a pyrazolinone derivative and lipoxygenase inhibitor that increases endogenous prostacyclin (PGI2) and has experimental anticancer activity. Nafazatrom is also an antithrombotic drug that increases prostacyclin levels and reduces the incidence of arrhythmias associated with cardiac injury.
Molecular Weight:
268.31
CAS Number:
[59040-30-1]
Formula:
C16H16N2O2
Target:
Lipoxygenase|||Others
T33579
* VAT and and shipping costs not included. Errors and price changes excepted
